title: Effect of a synthetic protease inhibitor (Fut-175) on coagulation abnormalities during experimental acute pancreatitis in dogs.
abstract: The coagulation disturbance observed during severe acute pancreatitis before and after the infusion of a new synthetic low molecular weight protease inhibitor (Fut-175) was compared. The coagulo-fibrinolytic changes after acute pancreatitis was induced by the intraductal injection of an autologous bile and trypsin mixture showed decreased platelet counts, decreased plasma fibrinogen levels, prolonged partial prothrombin time and increased fibrinogen degradation products. In addition, markers of hypercoagulation showed increased fibrin-peptide A and decreased antithrombin III. The two markers of fibrinolysis showed increased B beta 15-42 immunoreactive peptide and decreased alpha 2 antiplasmin. After the infusion of Fut-175, the coagulo-fibrinolytic abnormalities, which were observed during severe acute pancreatitis without infusion of Fut-175, were improved. Furthermore, Fut-175 could suppress the rise in fibrino-peptide A and B beta 15-42 immunoreactive peptide and decrease in antithrombin III and alpha 2 antiplasmin. Thus, Fut-175 seems to be an effective inhibitor of protease-mediated hypercoagulation and fibrinolysis in severe acute pancreatitis.
authors.affiliation: First Department of Surgery, Osaka City University Medical School, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Satake
authors.forename: S
authors.initials: S
authors.lastname: Ha
authors.forename: A
authors.initials: A
authors.lastname: Hiura
authors.forename: H
authors.initials: H
authors.lastname: Nishiwaki
authors.forename: A
authors.initials: A
authors.lastname: Haku
authors.forename: K
authors.initials: K
authors.lastname: Umeyama
mesh_terms: D000208:Acute Disease; D000818:Animals; D001550:Benzamidines; D001778:Blood Coagulation Disorders / Q000188:drug therapy* / Q000209:etiology; D001779:Blood Coagulation Factors / Q000032:analysis; D001780:Blood Coagulation Tests; D004285:Dogs; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D006146:Guanidines / Q000627:therapeutic use*; D008297:Male; D010195:Pancreatitis / Q000097:blood*; D011480:Protease Inhibitors / Q000627:therapeutic use*
chemical_list: D001550:Benzamidines; D001779:Blood Coagulation Factors; D006146:Guanidines; D011480:Protease Inhibitors; C032855:nafamostat